Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019
30 January 2020 - 10:35AM
Business Wire
Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the
“Company” or “Bioasis”), a pre-clinical,
research-stage biopharmaceutical company developing its
proprietary xB3 ™ platform technology for the delivery of
therapeutics across the blood-brain barrier (“BBB”) and the
treatment of central nervous system (“CNS”) disorders in areas of
high unmet medical need, including brain cancers and
neurodegenerative diseases, today announced it has filed its
unaudited quarterly financial statements and management’s
discussion and analysis for the period ended November 30, 2019. All
are available under the Company’s profile on SEDAR at www.sedar.com
and on the Company’s website at www.bioasis.us/investors/.
On behalf of the Board of Directors of Bioasis Technologies
Inc.
Deborah Rathjen, Ph.D., Director and President & Chief
Executive Officer
ABOUT BIOASIS
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3 ™ platform, a proprietary technology for the
delivery of therapeutics across the BBB and the treatment of CNS
disorders in areas of high unmet medical need, including brain
cancers and neurodegenerative diseases. The delivery of
therapeutics across the BBB represents the final frontier in
treating neurological disorders. The in-house development programs
at Bioasis are designed to develop symptomatic and
disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the
symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more
information about the company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
BTI-FIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200129005825/en/
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen deborah@bioasis.us +1 203 533 7082
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Jan 2025 to Feb 2025
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Feb 2024 to Feb 2025
